EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies

Nida Kalam, Vinod R M T Balasubramaniam iD

Influenza and Other Respiratory Viruses · 2024-12 · 18 (12)

DOI: 10.1111/irv.70064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 19.12.2024. Verfasst von Nida Kalam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia. Hauptthemen laut MEDLINE: Antiviral Agents, Central Nervous System Viral Diseases, Enterovirus D, Human, Enterovirus Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education, Malaysia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enterovirus‐D68 (EV‐D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV‐D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV‐D68 positive. WIN‐like compounds (pleconaril, pocapavir, and vapendavir) bind to the virus capsid and have been tested against various enteroviruses (EVs) in clinical trials. However, these compounds encountered issues with resistance and adverse effects, which impeded their approval by the Food and Drug Administration (FDA). Presently, the medical field lacks FDA‐approved antiviral treatments or vaccines for EV‐D68. Ongoing research efforts are dedicated to identifying viable therapeutics to address EV‐D68 infections. This review explores the current advancements in antiviral therapies and potential therapeutics to mitigate the significant impact of EV‐D68 infection control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCentral Nervous System Viral DiseasesEnterovirus D, HumanEnterovirus InfectionsMyelitisHumansUnited StatesNeuromuscular Diseases

Stichwörter der Autor:innen

WIN‐like compoundsacute flaccid myelitisbroad‐spectrum antiviralcontemporary strainsdrug‐resistanceenterovirus‐D68type‐I interferonviral life cycle

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.

ORCID-Profile: Vinod R M T Balasubramaniam

Förderung

  • Ministry of Higher Education, Malaysia

Zitieren

APA

Kalam, N., & Balasubramaniam, V. R. M. T. (2024). Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies. Influenza and Other Respiratory Viruses, 18(12). https://doi.org/10.1111/irv.70064

Vancouver

Kalam N, Balasubramaniam VRMT. Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies. Influenza and Other Respiratory Viruses. 2024;18(12). doi:10.1111/irv.70064

BibTeX
@article{Kalam2024,
  author = {Kalam, Nida and Balasubramaniam, Vinod R M T},
  title = {Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  volume = {18},
  number = {12},
  doi = {10.1111/irv.70064}
}
Kostenlos starten →